In contrast to our results, the study by Singh et al. showed that prostate cancer patients treated with intensity-modulated radiotherapy who had a higher grade of acute GU radiotoxicity had lower plasma TGF-β1 concentrations at the end of therapy and 3 months after therapy [55]. This evidence concerns the gene TGFB1 and Familial prostate cancer.